噻唑烷二酮类药物不良反应的再认识

被引：2

作者：

刘晓云

刘超

机构：

[1] 南京医科大学第一附属医院内分泌科

来源：

国际内分泌代谢杂志 | 2008年 / 06期

关键词：

噻唑烷二酮; 肝毒性; 体重; 心力衰竭; 心血管事件; 骨折;

D O I：

暂无

中图分类号：

R587.1 [糖尿病];

学科分类号：

1002 ; 100201 ;

摘要：

噻唑烷二酮类药物(TZDs)通过激活过氧化物酶体增殖物活化受体-γ,增加外周组织对胰岛素的敏感性而改善胰岛素抵抗,以其独特的作用机制在口服抗糖尿病药物中独树一帜。然而,近年来有关 TZDs 不良反应的报道日渐增多。在肝毒性、体重增加、水肿、心力衰竭等不良反应得到确认的同时,关于其心血管与骨代谢方面的不良反应更是备受关注。科学而合理地分析与认识这些不良反应,对指导临床实践具有重要意义。

引用

页码：369 / 373

共 6 条

[1] The safety of rosiglitazone in the treatment of Type 2 diabetes [J].

Singh, Sonal ;

Loke, Yoon K. .

EXPERT OPINION ON DRUG SAFETY, 2008, 7 (05) :579-585

[2]

Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone[J] . Adrian V. Hernandez,Esteban Walker,John P.A. Ioannidis,Michael W. Kattan.American Heart Journal . 2008 (1)

[3]

A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure[J] . Henry J. Dargie,Per R. Hildebrandt,Günter A.J. Riegger,John J.V. McMurray,Stephen O. McMorn,Jeremy N. Roberts,Andrew Zambanini,John P.H. Wilding.Journal of the American College of Cardiology . 2007 (16)

[4]

The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial[J] . Andrew Grey,Mark Bolland,Greg Gamble,Diana Wattie,Anne Horne,James Davidson,Ian R. Reid.The Journal of Clinical Endocrinology & Metabolism . 2007 (4)

[5] Thiazolidinedione use and bone loss in older diabetic adults [J].

Schwartz, Ann V. ;

Sellmeyer, Deborah E. ;

Vittinghoff, Eric ;

Palermo, Lisa ;

Lecka-Czernik, Beata ;

Feingold, Kenneth R. ;

Strotmeyer, Elsa S. ;

Resnick, Helaine E. ;

Carbone, Laura ;

Beamer, Brock A. ;

Park, Seok Won ;

Lane, Nancy E. ;

Harris, Tamara B. ;

Cummings, Steven R. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (09) :3349-3354

[6]

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association .2 Nesto RW,Bell D,Bonow RO,et al. Diabetes Care . 2004

← 1 →